Patents

 

  • US patent application 018617.01336. Filed on January 11, 2022
    Title: “Novel inflammasome agonists for augmenting immune responses”
    Inventor: Julie Magarian Blander

  • European patent number EP2531207, European Application No. EP11740492. Issued on October 30, 2019

    Title: “Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells”
    Inventors: Julie Magarian Blander and Johan Garaude

  • US patent number 9314484. Issued on April 19, 2016
    Application number 14/484,374. Filed on 09/12/2014
    Title: “Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells”
    Inventors: Julie Magarian Blander and Johan Garaude

    Provided are methods for inducing an anti-tumor immune response by immunizing a mammal with a composition comprising a tumor cell which expresses a Nod-like receptor (NLR) ligand and/or Toll-like receptor (TLR) ligand-tumor associated antigen (TAA) fusion protein or with an activated dendritic cells which has internalized a tumor cell that expresses an NLR- and/or TLR ligand-TAA fusion protein.

  • US patent number 9233154. Issued on January 12, 2016
    This is a divisional of US Application number 13/133,817. Filed on 12/13/2013
    Title: “T helper cell type 17 lineage-specific adjuvants, compositions and methods”
    Inventors: Julie Magarian Blander and Miriam Torchinsky

  • US patent number 8628762. Issued on January 14, 2014
    Application number 13/133,817. Filed on 12/09/2009
    Title: “T helper cell type 17 lineage-specific adjuvants, compositions and methods”
    Inventors: Julie Magarian Blander and Miriam Torchinsky

    The present invention relates to compositions and methods for the modulation of TH17 responses. The invention provides compositions for the induction of TH17 responses containing a TLR agonist and an apoptotic cell-associated agent or containing a microbe-infected apoptotic cell. The compositions of the present invention may also contain dendritic cells capable of inducing TH17 responses. In other embodiments, the invention provides compositions for the inhibition of TH17 responses containing one or more blocking agents. Methods and compositions for the modulation of TH17 responses and for the treatment of TH17-associated diseases and for cancer are also provided.

  • US patent number 10588964. Issued on March 17, 2020
    Continuation of US patent application 14/233,631. Filed on 11/10/2017
    Title: “Bacterial RNAs as vaccine adjuvants”
    Inventors: Julie Magarian Blander and Leif Erik Sander

    The invention features vaccine adjuvants comprising prokaryotic mRNA, and methods of vaccination using the adjuvants.

  • US patent number 9844592. Issued on December 19, 2017
    Application 14/233,631. Filed on 07/17/2012
    Title: “Bacterial RNAs as vaccine adjuvants”
    Inventors: Julie Magarian Blander and Leif Erik Sander

    The disclosure features vaccine adjuvants comprising prokaryotic mRNA, and methods of vaccination using the adjuvants. More specifically, the disclosure provides a vaccine composition comprising a nonviable immunogen (e.g., heat-killed bacterium), a tumor antigen, or an immunogenic peptide of microbial or mammalian origin, and an adjuvant, wherein adjuvant comprises prokaryotic mRNA (e.g., bacterial mRNA), as well as the methods of using the vaccine compositions. Further disclosed are the structural features of the prokaryotic mRNA used as the adjuvants.